These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958 [TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447 [TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267 [TBL] [Abstract][Full Text] [Related]
25. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716 [TBL] [Abstract][Full Text] [Related]
26. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908 [TBL] [Abstract][Full Text] [Related]
27. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473 [TBL] [Abstract][Full Text] [Related]
28. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517 [TBL] [Abstract][Full Text] [Related]
29. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Spear P; Barber A; Sentman CL Oncoimmunology; 2013 Apr; 2(4):e23564. PubMed ID: 23734311 [TBL] [Abstract][Full Text] [Related]
30. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. Lehner M; Götz G; Proff J; Schaft N; Dörrie J; Full F; Ensser A; Muller YA; Cerwenka A; Abken H; Parolini O; Ambros PF; Kovar H; Holter W PLoS One; 2012; 7(2):e31210. PubMed ID: 22355347 [TBL] [Abstract][Full Text] [Related]
31. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Evans LS; Witte PR; Feldhaus AL; Nelson BH; Riddell SR; Greenberg PD; Lupton SD; Jones LA Hum Gene Ther; 1999 Aug; 10(12):1941-51. PubMed ID: 10466628 [TBL] [Abstract][Full Text] [Related]
32. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy. Chen HW; Liao CH; Ying C; Chang CJ; Lin CM Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844 [TBL] [Abstract][Full Text] [Related]
33. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers. Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667 [TBL] [Abstract][Full Text] [Related]
36. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer. Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744 [TBL] [Abstract][Full Text] [Related]
37. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565 [TBL] [Abstract][Full Text] [Related]
39. The role of the NKG2D receptor for tumor immunity. Coudert JD; Held W Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326 [TBL] [Abstract][Full Text] [Related]
40. In vitro-activated tumor-bearing host T cells and the effectiveness of tumor vaccine immunotherapy. Li QL; Gao SF; Wang YP; Ma J; Feng CX; Wang Y; Wang YL Ann Saudi Med; 2012; 32(2):162-8. PubMed ID: 22366830 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]